RxDoctor Payments Data

Melissa Ortega, MD

Neurology · Miami, FLNPI 1962563841

Payments from drug & device makers

$2,907in general payments, 2019–2025

Across 56 payments — averaging $51.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$600
  • EMD Serono, Inc.$535
  • AstraZeneca$411
  • Sanofi$353
  • Novartis$274
  • Amgen$241
  • plus $493 from 12 others

What the payments were for

  • Food & beverage$2,80797%
  • Education$1013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,907 in reported general payments places this provider in the 50th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$341,271
Medicare patients
85
Services billed
7,378

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab34$298,520
CopaxoneGlatiramer Acetate40$246,266
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5025$154,992
Gamunex-CImmune Globul G/Gly/Iga Avg 4628$140,994
MayzentSiponimod13$124,843
Dalfampridine ErDalfampridine52$25,563
Glatiramer Acetate12$16,708
Carbamazepine ErCarbamazepine19$3,256
Baclofen73$1,234
Carbamazepine18$1,168
Gabapentin78$1,002
Modafinil26$935
Teriflunomide19$845
AmantadineAmantadine Hcl17$521
Tizanidine Hcl23$280

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$133$246,26640 claims
NovartisMayzent$274$124,84313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,434 neurology providers in Florida.

Other neurology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →